Rademikibart is an inhibitory human monoclonal antibody against the IL-4Rα, a common subunit for IL-4 and IL-13 receptors and a validated target for an FDA-approved therapy (Dupixent®). IL-4 and IL-13 are key Th2 cytokines with extensive overlapping functions, driving several inflammatory diseases. Preclinical and clinical data demonstrated that dual inhibition of IL-4 and IL-13 is required to achieve desired efficacy in Th2-mediated diseases.

​

Rademikibart binds to a distinct and unique region in IL-4Rα in a manner that prevents the receptor from interacting with other receptor subunits that are required for activation of the signaling pathways that ultimately give rise to Th2-mediated diseases, including atopic dermatitis and asthma.

​

Our clinical development program is focused on differentiating rademikibart in three areas: the potential to show rapid onset and sustained improvements in clinical outcomes with a convenient dosing frequency.

​

Rademikibart has shown dose-dependent and differentiated pharmacokinetics and pharmacodynamics in the following clinical trials.